Mineralys Therapeutics Announces Board and Executive Changes
Ticker: MLYS · Form: 8-K · Filed: Apr 4, 2024 · CIK: 1933414
Sentiment: neutral
Topics: management-change, compensation, governance
TL;DR
Board shakeup and exec comp changes at Mineralys. Keep an eye on new leadership.
AI Summary
Mineralys Therapeutics, Inc. announced on March 29, 2024, changes in its board of directors and executive compensation arrangements. The filing details the departure of certain officers and directors, the election of new directors, and updates to compensatory arrangements for key personnel. Specific details regarding the individuals involved and the financial implications of these changes are outlined within the report.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy, governance, or financial outlook, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in leadership and compensation can introduce uncertainty and signal underlying issues or strategic shifts.
Key Players & Entities
- Mineralys Therapeutics, Inc. (company) — Registrant
- March 29, 2024 (date) — Date of earliest event reported
FAQ
What specific roles have been affected by the departure of officers or directors?
The filing indicates changes in 'Departure of Directors or Certain Officers' and 'Appointment of Certain Officers,' suggesting shifts in key leadership positions, though specific roles are detailed within the full report.
When were these changes effective?
The earliest event reported is dated March 29, 2024.
What is the primary business of Mineralys Therapeutics, Inc.?
Mineralys Therapeutics, Inc. is in the business of Pharmaceutical Preparations, as indicated by its SIC code [2834].
Where is Mineralys Therapeutics, Inc. headquartered?
The company's principal executive offices are located at 150 N. Radnor Chester Road, Suite F200, Radnor, Pennsylvania 19087.
What is the filing number for this 8-K report?
The SEC file number for this 8-K report is 001-41614.
Filing Stats: 453 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2024-04-04 08:04:06
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share MLYS The Nasdaq Stock Marke
Filing Documents
- mlys-20240329.htm (8-K) — 23KB
- 0001933414-24-000008.txt ( ) — 151KB
- mlys-20240329.xsd (EX-101.SCH) — 2KB
- mlys-20240329_lab.xml (EX-101.LAB) — 23KB
- mlys-20240329_pre.xml (EX-101.PRE) — 13KB
- mlys-20240329_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: April 4, 2024 MINERALYS THERAPEUTICS, INC. By: /s/ Adam Levy Name: Adam Levy Title: Chief Financial Officer and Secretary